Enanta Pharmaceuticals Q3 revenue rises slightly

Enanta Pharmaceuticals

11/08/2025 21:21

Overview

Enanta fiscal Q3 revenue rises slightly to $18.3 mln, primarily from HCV royalties

Net loss narrows to $18.3 mln, driven by lower R&D and admin expenses

Outlook

Company expects cash and royalties to support operations into FY 2028

Result Drivers

ROYALTY REVENUE - Revenue driven by royalties from AbbVie's HCV regimen MAVYRET/MAVIRET

R&D EXPENSES - Decrease in R&D expenses due to timing of RSV clinical trials

LEGAL EXPENSES - Lower legal expenses following resolution of patent lawsuit against Pfizer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$18.31 mln
Q3 EPS
-$0.85
Q3 Net Income
-$18.26 mln
Q3 Operating Expenses
$37.21 mln
Q3 Operating Income
-$18.89 mln
Q3 Pretax Profit
-$18.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 65.5% above its August 8 closing price of $6.90

Press Release: ID:nBw205gwva

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)